IRVINE, Calif., May 12, 2011 /PRNewswire/ — Irvine
Pharmaceutical Services is excited to announce the addition of Dr.
Dorla Mirejovsky, as the Senior Director of Formulation
Development. Dr. Mirejovsky brings with her over 25 years of
experience in pharmaceutical development, drug delivery, and
manufacturing of injectable drugs.
Dr. Mirejovsky most recently was responsible for the development
and manufacture of several proprietary drug candidates at Spectrum
Pharmaceuticals. While at Spectrum Pharmaceuticals, Dr.
Mirejovsky authored CMC submissions for one NDA and several INDs.
Prior to Spectrum, she spent nine years at Sicor
Pharmaceuticals, Inc. developing numerous injectable products
including Propofol Injectable Emulsion. Additionally, Dr.
Mirejovsky has had similar roles at ISIS Pharmaceuticals, Inc. and
Dr. Mirejovsky holds a Ph.D. in Physical Organic Chemistry from
the University of Utrecht, Utrecht, The Netherlands preceded by a
Diplome d’ingenieur d’ENSCP – Ecole Nationale Superieure de Chimie
de Paris, Paris, France. She was a postdoctoral fellow at the
Department of Chemistry, Northwestern University, Evanston,
Illinois and at the Department of Chemistry, Duke University,
Durham, North Carolina.
You can learn more about Irvine and the executive team at the
2011 AAPS National Biotech Conference in San Francisco,
California, May 16-18, 2011. Visit us at our affiliate, Avrio
Biopharma’s booth 53!
Irvine Pharmaceutical Services, Inc. along with its affiliate,
Avrio Biopharma, is a premier contract development and
manufacturing organization providing support to the pharmaceutical,
biopharmaceutical, and medical device industries. Irvine and Avrio
together provide full cGMP specialized product development services